BRPI0516933A - métodos para o isolamento da haptoglobina humana, dos isoformas de hp humana individuais, e da albumina e da haptoglobina humana a partir da fração v de cohn humana, e, produto - Google Patents

métodos para o isolamento da haptoglobina humana, dos isoformas de hp humana individuais, e da albumina e da haptoglobina humana a partir da fração v de cohn humana, e, produto

Info

Publication number
BRPI0516933A
BRPI0516933A BRPI0516933-0A BRPI0516933A BRPI0516933A BR PI0516933 A BRPI0516933 A BR PI0516933A BR PI0516933 A BRPI0516933 A BR PI0516933A BR PI0516933 A BRPI0516933 A BR PI0516933A
Authority
BR
Brazil
Prior art keywords
human
haptoglobin
isoforms
methods
cohn fraction
Prior art date
Application number
BRPI0516933-0A
Other languages
English (en)
Inventor
Joan Dalton
Adrian Podmore
Peter Kumpalume
Original Assignee
Nhs Blood & Transplant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nhs Blood & Transplant filed Critical Nhs Blood & Transplant
Publication of BRPI0516933A publication Critical patent/BRPI0516933A/pt
Publication of BRPI0516933B1 publication Critical patent/BRPI0516933B1/pt
Publication of BRPI0516933B8 publication Critical patent/BRPI0516933B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MéTODOS PARA O ISOLAMENTO DA HAPTOGLOBINA HUMANA, DOS ISOFORMAS DE HP HUMANA INDIVIDUAIS, E DA ALBUMINA E DA HAPTOGLOBINA HUMANA A PARTIR DA FRAçãO V DE COHN HUMANA, E, PRODUTO. A invenção fornece um método para o isolamento da haptoglobina de uma amostra compreendendo a fração V de Cohn, em que referido método compreende a cromatografia de troca de ânions da referida amostra. O produto pode ser ainda purificado e/ou submetido a uma ou mais etapas de inativação ou redução viral. A haptoglobina isolada pode então ser formulada para uso farmacêutico.
BRPI0516933A 2004-10-19 2005-10-19 métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana BRPI0516933B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0423196.5 2004-10-19
GBGB0423196.5A GB0423196D0 (en) 2004-10-19 2004-10-19 Method
PCT/GB2005/004037 WO2006043062A1 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin

Publications (3)

Publication Number Publication Date
BRPI0516933A true BRPI0516933A (pt) 2008-09-23
BRPI0516933B1 BRPI0516933B1 (pt) 2021-02-09
BRPI0516933B8 BRPI0516933B8 (pt) 2021-05-25

Family

ID=33484812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516933A BRPI0516933B8 (pt) 2004-10-19 2005-10-19 métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana

Country Status (13)

Country Link
US (1) US9145448B2 (pt)
EP (1) EP1802654B1 (pt)
JP (1) JP4950053B2 (pt)
AT (1) ATE539085T1 (pt)
AU (1) AU2005297061B2 (pt)
BR (1) BRPI0516933B8 (pt)
CA (1) CA2584407C (pt)
ES (1) ES2379157T3 (pt)
GB (1) GB0423196D0 (pt)
IL (1) IL182340A (pt)
MX (1) MX2007004244A (pt)
PL (1) PL1802654T3 (pt)
WO (1) WO2006043062A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
EP2904005A1 (en) * 2012-10-03 2015-08-12 CSL Behring LLC A method of purifying proteins
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
WO2020160505A1 (en) * 2019-02-01 2020-08-06 Ohio State Innovation Foundation Methods of protein purification
WO2020236952A1 (en) * 2019-05-20 2020-11-26 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
WO2022169206A1 (ko) * 2021-02-04 2022-08-11 ㈜Gc녹십자 헤모펙신 및 합토글로빈의 정제 방법
CN115531921B (zh) * 2022-08-26 2024-07-16 大连依利特分析仪器有限公司 一种制备型液相色谱馏分收集装置及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5337406B2 (pt) * 1973-11-15 1978-10-09
US4061735A (en) 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
GB1426039A (en) 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4137307A (en) * 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
JPS52128205A (en) 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
JP3825061B2 (ja) * 1994-09-28 2006-09-20 三菱ウェルファーマ株式会社 ハプトグロビンの製造方法
DE19960500A1 (de) 1999-12-15 2001-07-12 Giesing Michael Antikörper und Verfahren zu ihrer Herstellung, deren Verwendung sowie Immunisierungscocktails, Immunoassay-Sets und Peptide
WO2002032941A2 (en) 2000-10-16 2002-04-25 Proteopharma Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
US20030113830A1 (en) 2001-07-11 2003-06-19 Rappaport Family Institute For Research In The Medical Sciences Novel antioxidant, nucleic acid constructs encoding same, pharmaceutical compositions containing same and use of same for reducing oxidative-stress
JP2004244348A (ja) * 2003-02-13 2004-09-02 Nihon Pharmaceutical Co Ltd パプトグロビンの精製法
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2006107708A1 (en) 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin

Also Published As

Publication number Publication date
BRPI0516933B1 (pt) 2021-02-09
US20090281282A1 (en) 2009-11-12
JP2008517046A (ja) 2008-05-22
ES2379157T3 (es) 2012-04-23
PL1802654T3 (pl) 2012-05-31
BRPI0516933B8 (pt) 2021-05-25
CA2584407C (en) 2015-02-03
WO2006043062A1 (en) 2006-04-27
IL182340A (en) 2012-06-28
GB0423196D0 (en) 2004-11-24
JP4950053B2 (ja) 2012-06-13
AU2005297061B2 (en) 2011-09-01
EP1802654A1 (en) 2007-07-04
US9145448B2 (en) 2015-09-29
EP1802654B1 (en) 2011-12-28
AU2005297061A1 (en) 2006-04-27
IL182340A0 (en) 2007-07-24
MX2007004244A (es) 2007-09-07
CA2584407A1 (en) 2006-04-27
ATE539085T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
EA201070611A1 (ru) Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
WO2007040650A3 (en) Apoptosis promoters
NO20072526L (no) Halvfaste C-klasse immunstimulerende oligonukleotider
EP1816990A4 (en) SYSTEMS, DEVICES AND METHODS FOR TREATING INTERVERTEBRAL DISORDERS
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
MX2009010765A (es) Anticuerpos anti-ige.
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
WO2005074607A3 (en) Method of treating hemolytic disease
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
WO2007084868A3 (en) Treatment of disorders by activation of the unfolded protein response
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
IL182340A0 (en) Method for the isolation of haptoglobin
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
DK1299130T3 (da) Fremgangsmåde til behandling og forebyggelse af smitsomme sygdomme

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIO PRODUCTS LABORATORY LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.